Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies
Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed objectives and criteria for a clinical trial involving Isatuximab, while adding a new section on hematological malignancies and a registry identifier.SummaryDifference13%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.4%
Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.